Pentwater Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Pentwater Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,184,021	Closed	-$140M	–	439
2021 Q1	$140M	Buy	1,184,021 +6,021	+0.5%	+$712K	1.34%	19
2020 Q4	$139M	Buy	1,178,000 +713,872	+154%	+$82.9M	1.68%	15
2020 Q3	$51.6M	Buy	464,128 +64,558	+16%	+$6.93M	0.67%	31
2020 Q2	$40.8M	Buy	399,570 +236,798	+145%	+$25.3M	0.73%	24
2020 Q1	$17.6M	Buy	162,772 +54,623	+51%	+$6.28M	0.29%	41
2019 Q4	$12.6M	Buy	108,149 +24,659	+30%	+$2.86M	0.21%	59
2019 Q3	$9.56M	Buy	+83,490	New	+$8.3M	0.15%	56

Pentwater Capital Management's CBPO Position: Q2 2021 in Review

Pentwater Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 1,184,021 shares — an estimated $140M sold.

Pentwater Capital Management first reported a position in CBPO in Q3 2019 and held it in 7 quarters. The position peaked at $140M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

Pentwater Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
Pentwater Capital Management sold 1,184,021 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $140M.
Pentwater Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2019 and held it in 7 quarters.
Pentwater Capital Management's China Biologic Products Holdings, Inc. position peaked at $140M in Q1 2021.
0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on Pentwater Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.